metformin has been researched along with Infections in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Infections: Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.
Excerpt | Relevance | Reference |
---|---|---|
"Compared with glimepiride, Sita/Met as an initial treatment led to significantly greater improvements in glycemic control and body weight changes, with a lower incidence of hypoglycemia, over 30 weeks." | 5.24 | Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. ( Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH, 2017) |
" Adverse effect rates were 64% with placebo, 63." | 1.43 | Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. ( Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I, 2016) |
"The prevalence of type 2 diabetes in Thailand is 9." | 1.36 | Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. ( Benjasuratwong, Y; Bunnag, P; Chetthakul, T; Deerochanawong, C; Komoltri, C; Kosachunhanun, N; Krittiyawong, S; Leelawatana, R; Mongkolsomlit, S; Ngarmukos, C; Plengvidhya, N; Pratipanawatr, T; Rawdaree, P; Suwanwalaikorn, S, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Byun, S | 1 |
Lee, E | 1 |
Lee, KW | 1 |
Kim, SS | 1 |
Kim, IJ | 1 |
Lee, KJ | 1 |
Park, JH | 1 |
Kim, YI | 1 |
Lee, YS | 1 |
Chung, SC | 1 |
Lee, SJ | 1 |
Romera, I | 1 |
Ampudia-Blasco, FJ | 1 |
Pérez, A | 1 |
Ariño, B | 1 |
Pfarr, E | 1 |
Giljanovic Kis, S | 1 |
Naderali, E | 1 |
Pratipanawatr, T | 1 |
Rawdaree, P | 1 |
Chetthakul, T | 1 |
Bunnag, P | 1 |
Ngarmukos, C | 1 |
Benjasuratwong, Y | 1 |
Leelawatana, R | 1 |
Kosachunhanun, N | 1 |
Plengvidhya, N | 1 |
Deerochanawong, C | 1 |
Suwanwalaikorn, S | 1 |
Krittiyawong, S | 1 |
Mongkolsomlit, S | 1 |
Komoltri, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus[NCT00993187] | Phase 4 | 292 participants (Actual) | Interventional | 2010-05-04 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline) (NCT00993187)
Timeframe: Baseline and Week 30
Intervention | kg (Least Squares Mean) |
---|---|
Sitagliptin/Metformin | -0.83 |
Glimepiride | 0.90 |
Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline). (NCT00993187)
Timeframe: Baseline and Week 30
Intervention | mg/dL (Least Squares Mean) |
---|---|
Sitagliptin/Metformin | -47.0 |
Glimepiride | -23.5 |
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline). (NCT00993187)
Timeframe: Baseline and Week 30
Intervention | Percent of total hemoglobin (Least Squares Mean) |
---|---|
Sitagliptin/Metformin | -1.5 |
Glimepiride | -0.7 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 30 weeks
Intervention | Participants (Number) |
---|---|
Sitagliptin/Metformin | 8 |
Glimepiride | 8 |
An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product. (NCT00993187)
Timeframe: Up to 32 weeks
Intervention | Participants (Number) |
---|---|
Sitagliptin/Metformin | 88 |
Glimepiride | 101 |
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). (NCT00993187)
Timeframe: Week 30
Intervention | Percentage of Participants (Number) |
---|---|
Sitagliptin/Metformin | 81.2 |
Glimepiride | 40.1 |
Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. (NCT00993187)
Timeframe: Up to Week 30
Intervention | Percentage of participants (Number) |
---|---|
Sitagliptin/Metformin | 5.5 |
Glimepiride | 20.1 |
1 review available for metformin and Infections
Article | Year |
---|---|
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Hu | 2017 |
1 trial available for metformin and Infections
Article | Year |
---|---|
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Th | 2017 |
2 other studies available for metformin and Infections
Article | Year |
---|---|
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease | 2016 |
Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death.
Topics: Aged; Asian People; Cardiovascular Diseases; Cause of Death; Diabetes Complications; Diabetes Mellit | 2010 |